Acceleron Pharma (NASDAQ:XLRN)‘s stock had its “hold” rating reissued by equities research analysts at Oppenheimer in a research report issued to clients and investors on Monday.

Several other analysts have also recently commented on XLRN. HC Wainwright restated a “buy” rating and set a $62.00 price target on shares of Acceleron Pharma in a report on Monday. Credit Suisse Group set a $51.00 price target on shares of Acceleron Pharma and gave the stock a “buy” rating in a report on Tuesday, November 14th. Royal Bank of Canada restated a “hold” rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. ValuEngine cut shares of Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Finally, Barclays raised their price target on shares of Acceleron Pharma from $42.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $44.56.

Acceleron Pharma (NASDAQ:XLRN) opened at $35.92 on Monday. Acceleron Pharma has a 1 year low of $23.07 and a 1 year high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.02. The business had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the firm posted ($0.55) earnings per share. sell-side analysts predict that Acceleron Pharma will post -2.65 earnings per share for the current fiscal year.

In other Acceleron Pharma news, major shareholder Corp /De/ Celgene bought 745,592 shares of Acceleron Pharma stock in a transaction on Monday, September 25th. The stock was purchased at an average cost of $37.00 per share, for a total transaction of $27,586,904.00. Following the completion of the purchase, the insider now directly owns 6,118,479 shares of the company’s stock, valued at $226,383,723. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP John D. Quisel sold 5,113 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total transaction of $196,441.46. Following the completion of the sale, the senior vice president now owns 57,918 shares of the company’s stock, valued at $2,225,209.56. The disclosure for this sale can be found here. 3.90% of the stock is owned by insiders.

Institutional investors have recently modified their holdings of the company. Quantbot Technologies LP lifted its stake in shares of Acceleron Pharma by 416.3% in the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 2,352 shares during the last quarter. Acrospire Investment Management LLC acquired a new stake in shares of Acceleron Pharma in the second quarter worth $110,000. BNP Paribas Arbitrage SA increased its position in Acceleron Pharma by 969.9% during the second quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 3,288 shares during the period. Teacher Retirement System of Texas increased its position in Acceleron Pharma by 14.3% during the second quarter. Teacher Retirement System of Texas now owns 3,817 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 477 shares during the period. Finally, Legal & General Group Plc increased its position in Acceleron Pharma by 33.8% during the first quarter. Legal & General Group Plc now owns 4,041 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,020 shares during the period. Institutional investors and hedge funds own 85.84% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Acceleron Pharma’s (XLRN) Hold Rating Reiterated at Oppenheimer” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/12/acceleron-pharmas-xlrn-hold-rating-reiterated-at-oppenheimer.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.